| |
|
A randomized, pilot trial to evaluate glomerular filtration rate by
creatinine or cystatin C in naïve
HIV-infected patients after tenofovir/emtricitabine in combination
with atazanavir/ritonavir or efavirenz.
Albini L, Cesana BM, Motta D, et al
J Acquir Immune Defic Syndr.
2011 Oct 11
Abstract
Once-daily antiretroviral therapy among
treatment-experienced Muslim patients fasting for the month of
Ramadan.
Yakasai AM, Muhammad H, Babashani M,
et al
Trop Doct. 2011 Sep 13
Abstract
Abacavir/Lamivudine Versus Tenofovir
DF/Emtricitabine as Part of Combination Regimens for Initial
Treatment of HIV: Final Results.
Sax PE,
Tierney C, Collier AC, et al
J Infect Dis. 2011
Oct;204(8):1191-1201.
Abstract
Comparison of Abacavir/Lamivudine and Tenofovir/Emtricitabine
Among Treatment-Naive
HIV-Infected Patients Initiating Therapy.
Tan DH, Chan K, Raboud J, et al
J Acquir Immune Defic Syndr.
2011 Sep 1;58(1):38-46.
Abstract
Randomized comparison of renal effects, efficacy, and safety with
once-daily abacavir/lamivudine versus
tenofovir/emtricitabine, administered with efavirenz, in
antiretroviral-naive, HIV-1-infected adults: 48-week
results from the ASSERT study.
Post FA, Moyle GJ, Stellbrink HJ, et al
J Acquir Immune Defic Syndr.
2010 Sep;55(1):49-57.
Abstract
Prevalence of low-level HIV-1 variants with reverse transcriptase
mutation K65R and the effect of antiretroviral
drug exposure on variant levels.
Kozal MJ,
Chiarella J, St John EP,
et al
Antivir Ther. 2011;16(6):925-9.
Abstract
A WEEK-IN-REVIEW FEATURED REPORT
Comparison of abacavir/lamivudine and
tenofovir/emtricitabine among treatment-naïve
HIV-infected patients initiating therapy.
Tan DH,
Chan K, Raboud J, Cooper C, et al
J Acquir Immune Defic Syndr.
2011 Jun 24.
Abstract
Peripheral and Central Fat Changes in Subjects Randomized to
Abacavir-Lamivudine or Tenofovir-Emtricitabine
With Atazanavir-Ritonavir or Efavirenz: ACTG Study A5224s.
McComsey GA, Kitch D,
Sax PE,
et al
Clin Infect Dis.
2011 Jul;53(2):185-96.
Abstract
A WEEK-IN-REVIEW FEATURED
REPORT
Protection against Rectal Transmission of an
Emtricitabine (FTC)-Resistant SHIV162p3M184V
Mutant by Intermittent Prophylaxis with Truvada.
Cong ME, Youngpairoj AS,
Zheng Q, et al
J Virol. 2011 Jun 1.
Abstract
Bone Mineral Density and Fractures in Antiretroviral-Naive Persons
Randomized to Receive
Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine
Along With Efavirenz or
Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of
ACTG A5202.
McComsey GA, Kitch D, Daar ES,
et
al
J Infect Dis.
2011 Jun;203(12):1791-801.
Abstract
Beliefs about antiretroviral therapy, treatment adherence and quality
of life in a 48-week randomised
study of continuation of zidovudine/lamivudine or switch to tenofovir
DF/emtricitabine, each with efavirenz.
Cooper V, Moyle GJ, Fisher M,
et al
AIDS Care.
2011 Apr 5:1-9.
Abstract
A WEEK-IN-REVIEW FEATURED REPORT
Pharmacological considerations for tenofovir and
emtricitabine to prevent HIV infection.
Anderson PL, Kiser JJ, Gardner EM,
et al
J Antimicrob Chemother.
2010 Nov 30.
Abstract |
A WEEK-IN-REVIEW FEATURED REPORT
Concomitant Administration of BILR 355/r with Emtricitabine/Tenofovir Disoproxil
Fumarate
Increases Exposure to Emtricitabine and Tenofovir: A Randomized, Open-Label,
Prospective Study.
Huang F, Scholl P, Huang DB,
et al
Basic Clin Pharmacol Toxicol.
2010 Oct 27.
Abstract |
Tolerability of HIV postexposure prophylaxis with
tenofovir/emtricitabine and
lopinavir/ritonavir tablet formulation.
Tosini W, Muller P,
Prazuck T, et al
AIDS. 2010 Aug 19
Abstract |
Pharmacokinetics and Bioavailability of an Integrase and Novel
Pharmacoenhancer-
Containing Single-Tablet Fixed-Dose Combination Regimen for the
Treatment of HIV.
German P, Warren D, West S, Hui J, Kearney BP.
J Acquir Immune Defic Syndr.
2010 Jul 30.
Abstract |
A WEEK-IN-REVIEW FEATURED REPORT
Randomized Comparison of Renal Effects, Efficacy, and Safety With
Once-Daily
Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With
Efavirenz,
in Antiretroviral-Naive, HIV-1-Infected Adults: 48-Week Results From
the ASSERT
Study.
Post FA, Moyle GJ, Stellbrink HJ, et al
J Acquir Immune Defic Syndr. 2010 Apr 24
Abstract |
A WEEK-IN-REVIEW FEATURED REPORT
Impact of Low Abundance HIV Variants on Response to Ritonavir-Boosted
Atazanavir or Fosamprenavir Given Once Daily with Tenofovir/Emtricitabine
in Antiretroviral-Naive HIV-Infected Patients.
Ross LL, Weinberg WG, Dejesus E, et al
AIDS Res Hum Retroviruses.
2010 Apr 9
Abstract |
Does choice of combination antiretroviral therapy (cART) alter changes in
cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected
individuals commencing cART? A randomized, controlled study.
Winston A, Duncombe C, Li PC, et al
Clin Infect Dis.
2010 Mar 15;50(6):920-9.
Abstract |
Safety and efficacy of tenofovir/emtricitabine plus nevirapine
in HIV-infected patients.
Labarga P, Medrano J,
Seclen E,
et al
AIDS. 2010 Feb 15.
Abstract |
Emerging mutations at virological failure of HAART combinations containing
tenofovir and lamivudine or emtricitabine.
Maserati R, De Silvestri A, Uglietti A, et al
AIDS. 2010 Jan 30.
Abstract |
A WEEK-IN REVIEW FESTERED REPORT
Switching the nucleoside reverse transcriptase
inhibitor backbone to
reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate +
emtricitabine promptly improves triglycerides and low-density lipoprotein
cholesterol in dyslipidaemic patients.
Valantin MA, Bittar R, de Truchis P,
et al
J Antimicrob Chemother. 2010 Jan 6
Abstract
|
A WEEK-IN-REVIEW FEATURED REPORT
Viral Load Decay in Antiretroviral-Naïve Patients Receiving Once-Daily Tenofovir
and Emtricitabine
plus Twice-Daily Nevirapine.
Amoroso A, Gilliam BL, Talwani R,
et al
HIV Clin Trials.
2009 Sep-Oct;10(5):320-3.
Abstract |
A WEEK-IN-REVIEW FEATURED REPORT
Lower limb high arterial flow induced by tenofovir and
emtricitabine treatment.
Periard D, Yerly P, Hayoz D,
et al
Antivir Ther.
2009;14(6):865-7.
Abstract |
Tenofovir-Emtricitabine-Efavirenz in HIV-1-Infected Adults in Senegal:
A 96-Week Pilot Trial in
Treatment-Naive Patients.
Landman R, Poupard M, Diallo M, et al
J Int Assoc Physicians AIDS Care
2009 Sep 15.
Abstract |
Complete Protection from Repeated Vaginal SHIV Exposures in Macaques
by a
Topical Gel Containing Tenofovir Alone or with Emtricitabine.
Parikh UM, Dobard C, Sharma S, et al
J Virol. 2009 Aug 5.
Abstract |
A
WEEK-IN-REVIEW-FEATURED REPORT
Development of HIV-1 Drug Resistance Through 144 Weeks in
Antiretroviral-
Naïve Subjects on Emtricitabine, Tenofovir Disoproxil Fumarate, and
Efavirenz
Compared With Lamivudine/Zidovudine and Efavirenz in Study GS-01-934.
Margot NA, Enejosa J, Cheng AK, et al
J Acquir Immune Defic Syndr.
2009 Jul 29
Abstract |
A Randomized Comparative Trial of Continued Zidovudine/Lamivudine or
Replacement
With Tenofovir Disoproxil Fumarate/Emtricitabine in Efavirenz-Treated
HIV-1-Infected
Individuals.
Fisher M, Moyle GJ, Shahmanesh M,
et al
J Acquir Immune Defic Syndr.
2009 Jun 25
Abstract |
A WEEK-IN-REVIEW FEATURED REPORT
Randomized, double-blind, placebo-matched, multicenter trial of
abacavir/lamivudine or
tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV
treatment.
Smith KY, Patel P, Fine D, et al
AIDS. 2009 Jun 17.
Abstract |
A WEEK-IN-REVIEW FEATURED REPORT
Switch from a ZDV/3TC-based Regimen to a Completely
Once Daily (QD) Regimen of
Emtricitabine/Tenofovir DF Fixed Dose
Combination plus a Third QD Agent (sonett).
Arasteh K, Weitner L, Fenske S, et al
Eur J Med Res. 2009
May 14;14(5):195-9.
Abstract |
A WEEK IN REVIEW FEATURED REPORT
Emtricitabine/Tenofovir Disoproxil Fumarate: In Combination with
a Protease Inhibitor in HIV-1 Infection.
Perry CM.
Drugs.
2009;69(7):843-57.
Abstract |
A Simplification Trial Switching From Nucleoside Reverse Transcriptase
Inhibitors to Once-Daily
Fixed-Dose Abacavir/Lamivudine or Tenofovir/Emtricitabine in
HIV-1-Infected Patients With Virological
Suppression.
Martínez E, Arranz JA, Podzamczer D,
et al
J Acquir Immune Defic Syndr.
2009 Apr 24.
Abstract |
Combination of Tenofovir and Emtricitabine plus Efavirenz: In Vitro
Modulation of ABC transporter and
Intracellular Drug Accumulation.
Bousquet L, Pruvost A, Guyot AC, et al
Antimicrob Agents Chemother. 2008
Dec 15
Abstract |
Pharmacokinetics of emtricitabine/tenofovir disoproxil fumarate and tacrolimus
at steady state
when administered alone or in combination.
Chittick GE, Zong J, Begley JA,. et al
Int J Clin Pharmacol Ther.
2008 Dec;46(12):627-36
Abstract
|
|
HIV
Indications
Truvada Main Page
Main
New/Newsworthy
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader